House Loses Medical Device Reform Architect To BIO
This article was originally published in The Gray Sheet
Rep. Jim Greenwood's (R-Penn.) experience drafting combination product legislation suggests BIO will be alert to shared opportunities in the biologics/device policy arena
You may also be interested in...
The House Energy & Commerce Committee will review FDA's conflict-of-interest procedures as part of an expanding probe that originally focused on National Institutes of Health employee consulting arrangements
Medtronic will draw on expertise from its three cardiac-related divisions to aid Genzyme in the development of a catheter-delivered cell therapy for cardiovascular disease
Rep. James Greenwood (R-Penn.) is exhorting device companies to convey to the Senate that medical liability reforms, including a product liability provision, are crucial to their industry